Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Confirmatory Trial Seeks To Show Survival Advantage
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
You may also be interested in...
The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.
A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.